Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives

Cephalalgia : an International Journal of Headache
Matthew SussmanJ Menzin

Abstract

Objectives To assess the cost-effectiveness of erenumab 140 mg ("erenumab") for the prophylactic treatment of episodic migraine and chronic migraine. Study design A hybrid Monte Carlo patient simulation and Markov cohort model was constructed to compare erenumab to no preventive treatment or onabotulinumtoxinA among adult ( ≥ 18 years) patients with episodic migraine and chronic migraine who failed prior preventive therapy from the US societal and payer perspectives. Methods Patients entered the model one at a time and were assigned to a post-treatment monthly migraine day category based on baseline monthly migraine days and treatment effect. Using monthly cycles, patients were followed for 2 years and accumulated costs and utilities associated with their post-treatment monthly migraine days. The primary outcome included the incremental cost-effectiveness ratio presented as cost per quality-adjusted life year gained. Results With an annual drug price of erenumab of $6900, treatment with erenumab in the societal perspective ranges from a dominant strategy versus no preventive treatment among chronic migraine patients to an incremental cost-effectiveness ratio of $122,167 versus no preventive treatment among episodic migraine pat...Continue Reading

References

Dec 1, 1982·The American Journal of Medicine·J R BeckJ P Kassirer
Dec 1, 1982·The American Journal of Medicine·J R BeckS G Pauker
Apr 12, 2001·Cephalalgia : an International Journal of Headache·G CaroL Black
Nov 23, 2006·Cephalalgia : an International Journal of Headache·J S BrownJ Menzin
Mar 27, 2007·Cephalalgia : an International Journal of Headache·Lj StovnerJ-A Zwart
Dec 12, 2007·Headache·Kevin HawkinsMarcia Rupnow
Jan 1, 2010·Journal of Occupational and Environmental Medicine·Walter F StewartRichard B Lipton
Jun 22, 2011·Cephalalgia : an International Journal of Headache·Krista A PayneAndrew M Blumenfeld
Oct 21, 2011·Cephalalgia : an International Journal of Headache·Ralph P InsingaMary E Hanson
Apr 25, 2012·Neurology·S D SilbersteinUNKNOWN Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
May 16, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Patrick J GillardSean D Sullivan
Nov 7, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·David GrimesUNKNOWN Canadian Nourological Sciences Federation
Jan 12, 2013·Cephalalgia : an International Journal of Headache·T J SteinerG L Birbeck
Jun 19, 2013·Cephalalgia : an International Journal of Headache·UNKNOWN Headache Classification Committee of the International Headache Society (IHS)
May 29, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·M Ruggeri
Aug 28, 2014·The New England Journal of Medicine·Peter J NeumannMilton C Weinstein
Dec 14, 2016·The Journal of Headache and Pain·I Aicua-RapunA L Guerrero
Nov 25, 2017·The New England Journal of Medicine·Peter J GoadsbyRobert A Lenz
Feb 7, 2018·The Journal of Headache and Pain·Andrew M BlumenfeldAubrey Manack Adams

❮ Previous
Next ❯

Citations

Mar 1, 2019·The Annals of Pharmacotherapy·Scott G GarlandJohn G Gums
Apr 1, 2020·Headache·Christina L SzperkaRobert E Shapiro
May 22, 2020·Expert Review of Neurotherapeutics·Eleonora De MatteisSimona Sacco
Jul 30, 2020·Cephalalgia : an International Journal of Headache·Hans-Christoph DienerUNKNOWN International Headache Society Clinical Trials Committee
Jul 16, 2019·Clinical Drug Investigation·Theodoros V GiannouchosParaskevi Koufopoulou
Jun 12, 2020·Therapeutic Advances in Neurological Disorders·Anna P AndreouGiorgio Lambru
Mar 17, 2020·Journal of Anaesthesiology, Clinical Pharmacology·Shuchita GargBrinder Vij
Oct 8, 2020·Headache·Susan TuElla Zomer
Feb 7, 2021·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Maria Michela CainazzoSimona Guerzoni
Feb 18, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Akira YuasaShunya Ikeda
May 27, 2021·Expert Opinion on Drug Safety·Christina I DeligianniMessoud Ashina
Sep 4, 2021·Current Medical Research and Opinion·Paolo Martelletti, Martina Curto

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.